EMD Serono, Inc. is an affiliate of Merck KGaA, Darmstadt, Germany. Together, EMD Serono and its affiliates offer potential partners a solid foundation upon which to build mutually rewarding relationships.
EMD Serono and
Theratechnologies entered into a collaboration and licensing agreement for the exclusive rights, by EMD Serono, Inc., to
EGRIFTA® (tesamorelin for injection) in the United States.
EGRIFTA® was approved by the FDA in November of 2010.
EGRIFTA® is a registered trademark of Theratechnologies Inc.
© 2011 EMD Serono, Inc. All rights reserved.